BASEL, SWITZERLAND--(Marketwire - December 10, 2012) - Basilea Pharmaceutica AG / Basilea
appoints Ronald Scott as CEO to succeed Anthony Man and expands
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basilea Pharmaceutica Ltd. (SIX: BSLN)
announced today that it has promoted Ronald Scott, previously Chief
Officer, to Chief Executive Officer effective January 1, 2013 to succeed
Man, MD, who has decided for personal reasons to leave the company as of
December 31, 2012.
"We are very pleased that Ron Scott will assume the role of CEO of Basilea
following the decision of Anthony Man to resign. Ron Scott is an esteemed
business leader in the pharmaceutical industry with a track record of
results and maintaining organization focus on business priorities. With
product candidates including highly competitive late-stage drugs in our
and a strong cash position, Basilea has unique prospects to further create
substantial shareholder value," commented Werner Henrich, chairman of
"Anthony Man is one of the most experienced and respected drug development
executives in industry with an exceptional track record in bringing drugs
through to the market. We sincerely thank him for his leadership, integrity
resilience in guiding Basilea through very rewarding and challenging times
wish him all the best for his future endeavors."
For the last year Ron Scott served as COO responsible for all of Basilea's
operations including technical operations, commercial activities and
Prior to his position as COO he served as Basilea's CFO. Ron Scott led the
company's equity financings and significant business transactions.
held senior management positions in the pharmaceutical industry with over
years of experience and in the financial sector.
Basilea's Management Committee has been enlarged to include Ms. Heidi
Head of Global Human Resources effective January 1, 2013. The Management
other members remain Prof. Dr. Achim Kaufhold, Chief Medical Officer since
2010; Dr. Ingrid Heinze-Krauss, Chief Technical Officer since 2006; Dr.
Kellenberger, Chief Scientific Officer since 2009; and Joachim Blatter,
Financial Officer since 2012.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and
the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research
development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd. ("Basilea") the company focuses on innovative
products in the therapeutic areas of bacterial infections, fungal
oncology, targeting the medical challenge of rising resistance and
to current treatment options.
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
or achievements of Basilea Pharmaceutica Ltd. to be materially different
any future results, performance or achievements expressed or implied by
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new information,
events or otherwise.
This press release can be downloaded from www.basilea.com.
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE